后脊髓灰质炎时代我国应用赛宾株灭活脊髓灰质炎疫苗免疫的可行性  

Feasibility Study of Using Sabin-IPV Immunization in Post-eradication Era in China

作　　者：车艳春[1] 姜莉[1] 邵聪文[1] 何春艳[1] 张云昆[1] 杨净思[1] 

机构地区：[1]中国医学科学院北京协和医学院医学生物学研究所,云南昆明650118

出　　处：《中国疫苗和免疫》2010年第1期72-75,共4页Chinese Journal of Vaccines and Immunization

摘　　要：在所有国家被证实全部阻断了脊髓灰质炎(脊灰)野病毒传播后,全球将停止使用口服脊灰减毒活疫苗(Oral Poliomyelitis Attenuated Live Vaccine,OPV)免疫,进入后脊灰时代。为此,世界卫生组织(WHO)提出了届时全面停止OPV的使用,并同步开始灭活脊灰病毒疫苗(Inactivated Poliovirus Vaccine,IPV)的免疫,发展中国家更应考虑应用廉价的赛宾(Sabin)株IPV(sIPV)免疫,直至最终根除脊灰。然而目前全球尚无开发成功的sIPV上市。现介绍WHO推荐的这一免疫策略,分析全球sIPV的研发现状,从免疫策略、免疫程序、生产技术、疫苗供应等方面探讨我国应用sIPV免疫的可行性。鉴于这些可行性,我国应尽快推进sIPV的研发进程,为脊灰免疫策略的调整、实施做好准备。Based upon the World Health Organization （WHO）＇ s perspective, the post-eradication era is coming with a priority of global certifying the wild poliovirus eradication, by which then the Oral Poliomyelitis Attenuated Live Vaccine （OPV）will be ceased and Inactivated Poliovirus Vaccine （IPV） will be synchronized used, in particular the affordable Sabin-IPV （sIPV）is recommended to be used continuously in developing countries till the final eradication of poliomyelitis. However, no any sIPV has successfully been developed in the world. In this paper, the sIPV immunization strategy, current development status and its usage in industrialized countries are preliminarily analyzed. Feasibility analysis of potential sIPV usage in China, including immunization strategy, schedule, production technology and supply capacity is analysed as well. sIPV development in China should be accelerated in order to prepare production technology to the post-eradication era.

关 键 词：后脊髓灰质炎时代 赛宾株灭活脊髓灰质炎病毒疫苗 免疫 可行性探讨 

分 类 号：R512.4[医药卫生—内科学] R186[医药卫生—临床医学]